Anas Younes is the Senior Vice President and Global Head of Hematology (Early and Late Stage) Oncology R&D at AstraZeneca. Prior to working for AstraZeneca, he was the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, and a Professor of Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX.
Prof. Younes received his medical degree at Damascus University, Damascus, Syria, and subsequently completed residencies in pathology at the College of Medicine and Life Sciences at the University of Toledo, Toledo, OH, and in internal medicine at the State University of New York Downstate Medical Center, Brooklyn, NY. Prof. Younes then completed a fellowship in medical oncology at MSKCC, New York, NY.
Speaking on Hodgkin and non-Hodgkin lymphoma
Prof. Younes has spent more than 25 years caring for patients with lymphoma and lead numerous clinical trials that advanced the field. His research resulted in the US Food and Drug Administration approval of two novel agents for patients with Hodgkin lymphoma, including the first targeted drug for the treatment of Hodgkin lymphoma in more than three decades (brentuximab vedotin), and the approval of the first immune checkpoint inhibitor for lymphoma (nivolumab).
Prof. Younes has recently been involved in research regarding emerging epigenetic-modulating therapies in lymphoma, as well as in a Phase I trial investigating the safety and tolerability of CUDC-907, a dual inhibitor of HDAC and PI3K, in patients with relapsed/refractory lymphoma or multiple myeloma.